Home » Topics » Regulatory » EMA

EMA
RSS

Bristol-Myers Squibb's Yervoy recommended for approval in Europe for pediatric melanoma

Dec. 19, 2017

EMA committee recommends approval of Alkindi for pediatric adrenal insufficiency

Dec. 18, 2017

EMA committee recommends approval of Ozempic for type 2 diabetes

Dec. 18, 2017

Celltrion's trastuzumab biosimilar recommended for E.U. approval

Dec. 18, 2017

EMA committee hands down positive opinion on burosumab for X-linked hypophosphatemia

Dec. 18, 2017

CHMP grants positive opinion to Cx601 for the treatment of perianal fistulas in Crohn's disease

Dec. 18, 2017

EMA's CHMP requests additional information for betrixaban MAA

Dec. 13, 2017

EMA validates application for Opdivo plus Yervoy in advanced renal cell carcinoma

Dec. 1, 2017

EMA gives orphan drug designation to ProQR Therapeutics' QR-313

Nov. 30, 2017

EMA grants orphan drug designation for DCC-2618 as treatment of gastrointestinal stromal tumors

Nov. 30, 2017

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 6, 2025.
MJFF grant supports Bexorg’s translational biomarker work
BioWorld Science
Bexorg Inc. has been awarded a research grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) through the Targets to Therapies initiative to...
REST emerges as biomarker in ALS, knockdown improves ALS symptoms
BioWorld Science
About 10% of amyotrophic lateral sclerosis (ALS) cases result from inherited genetic mutations, with about 20% of them attributed to mutations in the gene...
Serotonin receptor modulators for the treatment of OUD
BioWorld Science
Opioid use disorder (OUD) causes high morbidity and mortality rates, with fentanyl driving unprecedented overdose rates. Researchers from the University of...
KLF15 shows potential as marker, target for cholangiocarcinoma
BioWorld Science
Researchers at the Biodonostia Health Research Institute reported on the role of KLF15 in cholangiocarcinogenesis and its potential as a therapeutic target in...